Clinical Trial Update: Saypha® VOLUME Lidocaine for Midface Augmentation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Saypha VOLUME Lidocaine for midface augmentation in moderate to severe midface volume deficit has completed and posted the results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Midface Volume Deficit

Drugs mentioned

• Saypha Volume Lidocaine (Hyaluronic acid dermal filler with lidocaine)

Snippet

Sponsor: Croma-Pharma GmbH | Conditions: Moderate to Severe Midface Volume Deficit | Phase 3 | Status: COMPLETED | Results posted: 2025-01-16